ARDX · Ardelyx Inc

-

Please sign in to comment on ARDX

1 Comment

Admin

4 years ago

Ardelyx, Inc is currently in a long term uptrend where the price is trading 16.7% above its 200 day moving average.

From a valuation standpoint, the stock is 93.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 89.6.

Ardelyx, Inc's total revenue sank by 19.6% to $2M since the same quarter in the previous year.

Its net income has dropped by 45.9% to $-29M since the same quarter in the previous year.

Finally, its free cash flow fell by 55.6% to $-18M since the same quarter in the previous year.

Based on the above factors, Ardelyx, Inc gets an overall score of 2/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US0396971071
Sector	Healthcare
Industry	Biotechnology

Market Cap	1B
PE Ratio	None
Target Price	10.75
Beta	0.81
Dividend Yield	None

ABOUT

Ardelyx Inc

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

ARDX · Ardelyx Inc

-

Ardelyx Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Ardelyx Inc using a moving average strategy